Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study

被引:9
作者
Zhou, Huiyu [1 ]
Zhu, Mei [1 ]
Ma, Ling [1 ]
Zhou, Jinming [2 ]
Dong, Biao [1 ]
Zhang, Guoning [1 ]
Cen, Shan [1 ]
Wang, Yucheng [1 ]
Wang, Juxian [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing, Peoples R China
[2] Zhejiang Normal Univ, Key Lab, Minist Educ Adv Catalysis Mat, Dept Chem, Jinhua, Zhejiang, Peoples R China
来源
PLOS ONE | 2020年 / 15卷 / 07期
关键词
OPTIMIZATION; AMINE;
D O I
10.1371/journal.pone.0235483
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A series of potent HIV-1 protease inhibitors, containing diverse piperidine analogues as the P2-ligands, 4-substituted phenylsulfonamides as the P2'-ligands and a hydrophobic cyclopropyl group as the P1'-ligand, were designed, synthesized and evaluated in this work. Among these twenty-four target compounds, many of them exhibited excellent activity against HIV-1 protease with half maximal inhibitory concentration (IC50) values below 20 nM. Particularly, compound 22a containing a (R)-piperidine-3-carboxamide as the P2-ligand and a 4-methoxylphenylsulfonamide as the P2'-ligand exhibited the most effective inhibitory activity with an IC50 value of 3.61 nM. More importantly, 22a exhibited activity with inhibition of 42% and 26% against wild-type and Darunavir (DRV)-resistant HIV-1 variants, respectively. Additionally, the molecular docking of 22a with HIV-1 protease provided insight into the ligand-binding properties, which was of great value for further study.
引用
收藏
页数:12
相关论文
共 35 条
  • [1] Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: new features identified
    Amin, S. A.
    Adhikari, N.
    Bhargava, S.
    Jha, T.
    Gayen, S.
    [J]. SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2018, 29 (05) : 385 - 408
  • [2] [Anonymous], 1981, MORBIDITY MORTALITY, V30
  • [3] Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
    Aoki, Manabu
    Das, Debananda
    Hayashi, Hironori
    Aoki-Ogata, Hiromi
    Takamatsu, Yuki
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    [J]. MBIO, 2018, 9 (02):
  • [4] A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency
    Aoki, Manabu
    Hayashi, Hironori
    Rao, Kalapala Venkateswara
    Das, Debananda
    Higashi-Kuwata, Nobuyo
    Bulut, Haydar
    Aoki-Ogata, Hiromi
    Takamatsu, Yuki
    Yedidi, Ravikiran S.
    Davis, David A.
    Hattori, Shin-ichiro
    Nishida, Noriko
    Hasegawa, Kazuya
    Takamune, Nobutoki
    Nyalapatla, Prasanth R.
    Osswald, Heather L.
    Jono, Hirofumi
    Saito, Hideyuki
    Yarchoan, Robert
    Misumi, Shogo
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    [J]. ELIFE, 2017, 6
  • [5] Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation
    Bai, Xiaoguang
    Yang, Zhiheng
    Zhu, Mei
    Dong, Biao
    Zhou, Lei
    Zhang, Guoning
    Wang, Juxian
    Wang, Yucheng
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 137 : 30 - 44
  • [6] Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents
    Bell, Jessica L.
    Haak, Andrew J.
    Wade, Susan M.
    Kirchhoff, Paul D.
    Neubig, Richard R.
    Larsen, Scott D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (13) : 3826 - 3832
  • [7] Biofocus PLC, 2004, [No title captured], Patent No. [WO2004/58259 2004 A1, 200458259]
  • [8] Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors
    Bungard, Christopher J.
    Williams, Peter D.
    Schulz, Jurgen
    Wiscount, Catherine M.
    Holloway, M. Katharine
    Loughran, H. Marie
    Manikowski, Jesse J.
    Su, Hua-Poo
    Bennett, David J.
    Chang, Lehua
    Chu, Xin-Jie
    Crespo, Alejandro
    Dwyer, Michael P.
    Keertikar, Kartik
    Morriello, Gregori J.
    Stamford, Andrew W.
    Waddell, Sherman T.
    Zhong, Bin
    Hu, Bin
    Jo, Tao
    Diamond, Tracy L.
    Bahnck-Teets, Carolyn
    Carroll, Steven S.
    Fay, John F.
    Min, Xu
    Morris, William
    Ballard, Jeanine E.
    Miller, Michael D.
    McCauley, John A.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (12): : 1292 - 1297
  • [9] Delino NS, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02060-17, 10.1128/aac.02060-17]
  • [10] Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1′ ligand
    Dou, Yue
    Zhu, Mei
    Dong, Biao
    Wang, Ju-Xian
    Zhang, Guo-Ning
    Zhang, Fan
    Wang, Yu-Cheng
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (07)